'Pharma Headline' Blonde Technology Wins $6.9 Billion Mask Order from U.S. Company

(2020/05/19) 69% more efficient than Truvada! ViiV early termination of an HIV prevention phase 3 trial; Moderna's new crown vaccine breakthrough vaccine to save the world's script to save the world staged around the world; the retail price of Naypyia in Guangdong Province dropped by 86% per box 8.9 yuan; the injection consistency evaluation officially launched will be good for these four sectors ..On May 18, ViiVHealthcare, a shareholder of GlaxoSmithKline, Pfizer and Yanno, announced positive interim results of a trial to evaluate the safety and efficacy of the long-acting injection cabotegravirThe data show that cabotegravir has an effective rate of 69% (95 percent CI: 41-84 percent) in preventing male behavior and sexual lying with men compared to the current standard of care, daily oral oral antofafenpheta (FTC/TDF, Truvada)The study reached the main end of the non-disadvantageViiV is also actively seeking a slice of the PrEP marketrecently, the State Drug Administration's Professional Pharmacist Qualification Center released the "April 2020 National Register of Practicing Pharmacists." The latest figures show that by the end of April 2020, there were 528,610 registered pharmacists nationwide, an increase of 5406 from the previous monthThe number of practicing pharmacists per 10,000 population is 3.8There are 477,875 practicing pharmacists registered in pharmaceutical retail enterprises, accounting for 90.4% of the total number of registered pharmacistspracticing pharmacists cannot be replacedlast night, Moderna, a U.Sbio-science company, released early human trial data for the new coronavirus vaccine mRNA-1273: all 45 subjects produced antibodies, the first 8 produced neutralizing antibodies, and the minimum dose (25 micrograms) group had antibody levels comparable to those recovered from new coronary pneumonia on the 43rd day of the trial, while the 100 micrograms "significantly exceeded this level" and there were no serious adverse reactions in the trialwill be a dead bonerecently, The official WeChat of Dasanlin Pharmaceutical Services issued a series of news to the outside world that the commonly used medicine for diabetes, Bai Tang, arrived at a price of only 8.9 yuanMoreover, according to the announcement of Dasanlin, the current sale of German imports Baitang is mainly divided into two dosage forms: one for the specification of 50mg x 30 tablets for 8.9 yuan / box, and the other for 100mg x 30 tablets for 15.9 yuan / boxthe biggest beneficiaries of the price cut were the drugstore chains18, Jinfa Technology Co., Ltdannounced that its subsidiary Guangdong Blonde Technology Co., Ltdrecently received a U.Scompany KN95 mask purchase order, the order amount of 975 million U.Sdollars, equivalent to about 6.94 billion yuanIf the successful completion of this KN95 mask contract, will significantly pull the full-year performance of blonde technologyAccording to the announcement, the successful performance of this contract is expected to generate a total net profit of more than 50% of the Company's audited net profit for 2019, which will have a positive impact on the company's operating results for the 2020 yearthere may also be risks such as certification licensing policiesthe design and execution of clinical studies with children as subjects face more difficulties and challenges than adult studies, making trials difficult or slow, and therefore, according to the design and research methods of traditional clinical trials, seriously affect the clinical availability of children's drugs and obtain sufficient data to assess the reasonableness of the dose of childrenOn 18 May, the Drug Review Center of the State Drug Administration issued the Technical Guidelines for Real World Evidence supporting the Development and Review of Children's Drugs (Draft for Comments) for public consultationuse real-world evidence to support children's drug research and development is in the stage of gradual construction and improvementon May 14,, the State Drug Administration issued a "Announcement on the Implementation of the Conformity Evaluation of the Quality and Efficacy of Chemical Injection Sasis" (hereinafter referred to as the "Announcement"), which made it clear that generic drugs for chemical injections that have been listed and that varieties that have not been approved in accordance with the principle of consistency with the quality and efficacy of the original drugs should be evaluated in accordance with the principles of conformity with the quality and efficacy of the original drugsThis means that the injection consistency evaluation officially launched, the industry concentration will usher in a significant increasethe evaluation of injection consistency also had a positive impact on the stock marketrecently, Henan Province Public Resources Trading Center announced the "Notice on the publicity of the first quarter of 2020 drug online trading in our province", announced the total amount of orders in the first quarter of Henan Province, the total amount of distribution, the total amount of storage, the number of purchased varieties year-on-year, month-on-month changesFrom the data point of view, the notice shows that, affected by the outbreak of the new coronavirus, the first quarter of the drug online transaction amount year-on-year, month-on-month have a significant declineAmong them, the order amount decreased by 23.16% YoY, the distribution amount decreased by 17.61% YoY, and the amount of deposit decreased by 14.07% YoY Henan province is not radical or conservative in its drug procurement policy recently, Suzhou City Health Insurance Bureau issued a request for comments on the "Suzhou City Fixed-point Outpatient Department, Clinic Credit Rating Management Measures (Trial)" to revise the draft, Sword refers to strengthening the supervision of medical security funds, strengthen the fixed-point outpatient departments, clinics self-discipline and integrity awareness, guide the integrity of the profession in accordance with the law, the "Measures" from July 1, 2020 this model will be rolled out across the country WHO has designated 19 May each year as World Day for Inflammatory Bowel Disease, and at first glance, many people may not know what kind of disease it is In this sad memory, the era model of the Chinese Academy of Sciences - drug scientist Wang Yiping researcher, is suffering from the disease for many years, and eventually left the love of the pharmaceutical career How much do we know about this debilitating, declining quality of life, and life-long treatment of this intestinal disease? What stage of drug development has it been? believe that the prospect of a cure will become clearer! , globalData recently released a new industry report, the U.S Food and Drug Administration (FDA) in 2019 the number of new drug approvals fell by about 16% According to globalData's 10th edition of the Pharmaceutical Contract Manufacturing Organization Industry Report ,"PharmSource-CMOScorecard: OutsourcingofNDA Approvals and CMOPerformance-2020 Editions" showed that the FDA approved 119 applications for new drug listings and licenses for biologics in 2019, including new molecular entities and new dosage forms for existing drugs This is a 3 per cent increase from an average of 115 in 2014-2018, but a nearly 16 per cent decrease from the 137 approval records recorded in 2018 new drug approvals from the simple demand spree for most people recently, the field of contrast agent singivation agent sings Hengrui medicine and raw materials drug leader Secretary Tai Li official announced cooperation, causing concern in the industry Immediately after, The first contrast agent preparation product was approved, Hengrui re-submitted the application for registration of the injection of meldonamuch According to Minet data, in 2019 China's public medical institutions terminal contrast agent sales of 15.210 billion yuan, sales of more than 1 billion yuan of brands have 7 With The first evaluation of the contrast agent, injection consistency evaluation officially launched, drug review and approval and national collection speed up, Hengrui revenue of more than 3.2 billion yuan contrast agent will face the challenge of collection, and Stelie's cooperation intention is self-evident Hengrui, Shi Taili two major contrast agent leader hug group, what is the intention?